FSHD is one of the most common forms of muscular dystrophyacross populations. The progressive loss of skeletal muscle strength in FSHD causes patients to losephysical function and quality of life. Despite this heavy public health burden, there has been a paucity ofclinical trials in FSHD, and no effective therapeutic agents have been identified or developed for FSHD.Since the basic pathophysiology of FSHD is unknown, a disease specific approach to therapy is notimminent. However, more general targets, such as those involved in muscle regeneration, may provebeneficial. We have found that inhibition of an endogenous growth factor, myostatin, stimulates muscleregeneration from acute and chronic injury and ameliorates disease features in the mdx mouse model ofmuscular dystrophy. Several inhibitors of myostatin have been recently developed by industry. ACE-031 isa novel protein therapeutic developed by Acceleron Pharma, Inc. (Cambridge, MA) comprised of theextracellular domain of ActRIIB fused to human IgG that binds avidly to myostatin and other negativeregulators of muscle mass and inhibits their biological effect. ACE-031 rapidly produces muscle growth inwild-type animals and stimulates muscle regeneration in models of muscular dystrophy. Acceleron hasdeveloped GMP-grade ACE-031 drug product for clinical trials in muscle disease. Animal Pharmacologyand Toxicology Studies are currently underway to support the initial human studies of ACE-031. Accerelonanticipates submitting an IND application to the FDA in early 2008. The goal of Project 1 of the FSHDWellstone is to generate all the necessary data and protocols for a successful efficacy trial of ACE-031 inFSHD.
Three specific aims will be addressed to meet this goal.
In Aim 1, we will collaborate with Acceleronto conduct a randomized, double-blind, placebo-controlled, multiple-dose, dose escalating clinical trial toevaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of ACE-031 (ActRIIB-lgG1)in healthy volunteers. Biological material from this healthy volunteer trial will be studied to determine amolecular signature of myostatin inhibition in the laboratory of Lou Kunkel in Aim 2. Pharmacokinetic,pharmacodynamic and biomarker data from Aims 1 and 2 will be used for Aim 3: the development of aPhase l/ll trial of ACE-031 in adult FSHD. During the award period, this trial will be designed to examine ifadministration of ACE-031 can lead to an increase in muscle strength and muscle

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54HD060848-01
Application #
7536208
Study Section
Special Emphasis Panel (ZAR1-KM-J (M1))
Project Start
2008-09-10
Project End
2013-08-31
Budget Start
2008-09-10
Budget End
2009-08-31
Support Year
1
Fiscal Year
2008
Total Cost
$90,415
Indirect Cost
Name
Boston Biomedical Research Institute
Department
Type
DUNS #
058893371
City
Watertown
State
MA
Country
United States
Zip Code
02472
Leung, Doris G; Wang, Xin; Barker, Peter B et al. (2018) Multivoxel proton magnetic resonance spectroscopy in facioscapulohumeral muscular dystrophy. Muscle Nerve 57:958-963
Wallace, Lindsay M; Saad, Nizar Y; Pyne, Nettie K et al. (2018) Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD. Mol Ther Methods Clin Dev 8:121-130
Giesige, Carlee R; Wallace, Lindsay M; Heller, Kristin N et al. (2018) AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD. JCI Insight 3:
Chagarlamudi, Hema; Corbett, Alastair; Stoll, Marion et al. (2017) Bone health in facioscapulohumeral muscular dystrophy: A cross-sectional study. Muscle Nerve 56:1108-1113
Eichinger, Katy; Heatwole, Chad; Heininger, Susanne et al. (2017) Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy. Muscle Nerve 55:333-337
Ansseau, Eugénie; Vanderplanck, Céline; Wauters, Armelle et al. (2017) Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD). Genes (Basel) 8:
Shaw, Natalie D; Brand, Harrison; Kupchinsky, Zachary A et al. (2017) SMCHD1 mutations associated with a rare muscular dystrophy can also cause isolated arhinia and Bosma arhinia microphthalmia syndrome. Nat Genet 49:238-248
Widrick, Jeffrey J; Alexander, Matthew S; Sanchez, Benjamin et al. (2016) Muscle dysfunction in a zebrafish model of Duchenne muscular dystrophy. Physiol Genomics 48:850-860
Chen, Jennifer Cj; King, Oliver D; Zhang, Yuanfan et al. (2016) Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics. Mol Ther 24:1405-11
Ansseau, Eugénie; Eidahl, Jocelyn O; Lancelot, Céline et al. (2016) Homologous Transcription Factors DUX4 and DUX4c Associate with Cytoplasmic Proteins during Muscle Differentiation. PLoS One 11:e0146893

Showing the most recent 10 out of 34 publications